Alzheimer’s Blood Test for Early Detection

Ariana Wilson and Mark Drlik seated against a white background, wearing lavalier microphones. The woman on the left has long brown curly hair and is wearing a beige cardigan over a taupe top. The man on the right is wearing glasses and a blue button-up shirt. They appear to be engaged in conversation or a video interview.
Resources

Alzheimer’s Blood Test for Early Detection

Sector: Diagnostics

In this episode of MedDevice by Design, we explore a groundbreaking shift in how Alzheimer’s disease may soon be diagnosed. Instead of relying on invasive spinal taps or costly PET scans, researchers have developed a blood test that detects key proteins associated with the disease—offering a more accessible and patient-friendly screening method.

A Simpler Diagnostic Pathway

Traditionally, Alzheimer’s diagnosis has required expensive imaging or invasive cerebrospinal fluid collection. This new approach allows patients to have their blood drawn at a standard medical office, with labs analyzing the sample for specific biomarkers. If these proteins are detected, the patient may then be referred for confirmatory tests and begin treatment earlier.

Supporting Earlier Treatment and Better Research

Early detection is crucial for effective treatment. Many Alzheimer’s drugs are more beneficial when administered during the disease’s early stages. This blood test can identify potential patients sooner, improving clinical outcomes. It also helps pharmaceutical companies recruit participants for trials and monitor drug efficacy over time.

Barriers to Widespread Use

While promising, the Alzheimer’s blood test still faces some hurdles. It’s currently a laboratory-developed test (LDT) and has not yet received FDA approval. Because of this, it’s often not covered by insurance and remains a costly out-of-pocket option for most people.

A Look Ahead

The potential impact of this innovation is immense. By making early Alzheimer’s detection more accessible, the test could transform clinical care and research. As approval processes advance and accessibility improves, this technology may reshape how we diagnose and treat neurodegenerative conditions.

X-ray image of a human chest showing bones in high contrast. A visible electronic device, likely a pacemaker or implant, is located in the upper left chest area. A bold red arrow points to the device with a label in black and white text reading “definitely not bone.”

Mark and Ariana explore the surprising versatility of barium sulfate—a material used widely in both diagnostic procedures and medical device manufacturing. While many recognize it as the contrast agent you drink before an X-ray, it’s also a key additive that enhances plastic components across the healthcare industry.

Gloved hand holding a test tube filled with red liquid, with a large red arrow pointing at the tube on a blue gradient background.

We explore a groundbreaking shift in how Alzheimer’s disease may soon be diagnosed. Instead of relying on invasive spinal taps or costly PET scans, researchers have developed a blood test that detects key proteins associated with the disease—offering a more accessible and patient-friendly screening method.

A bearded man in a denim shirt uses a handheld breathalyzer device. To the left, bold text reads: "How Breath Testing REALLY works," with the word "REALLY" emphasized in bright purple.

We explore how breath testing in medical devices is transforming diagnostics. Mark Drlik walks through how this technology supports everything from roadside impairment detection to gastrointestinal analysis.

A transparent capsule-shaped ingestible medical device is shown on the right, revealing internal electronics, circuits, and components. On the left, bold purple text reads “Ingestible Medical Devices” against a clean white background.

Mark Drlik and Ariana Wilson introduce the fascinating world of ingestible capsules—tiny, swallowable medical devices that are revolutionizing gastrointestinal health monitoring and targeted therapy.